218 related articles for article (PubMed ID: 29796928)
1. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
[TBL] [Abstract][Full Text] [Related]
2. Overview of Clinical Trial Program and Applicability of Insulin Degludec/Insulin Aspart in Diabetes Management.
Bantwal G; Wangnoo SK; Shunmugavelu M; Nallaperumal S; Harsha KP; Bhattacharyya A
J Assoc Physicians India; 2015 May; 63(5 Suppl):21-8. PubMed ID: 26548031
[TBL] [Abstract][Full Text] [Related]
3. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
[TBL] [Abstract][Full Text] [Related]
4. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of the co-formulation of insulin degludec and insulin aspart.
Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
7. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
8. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
[TBL] [Abstract][Full Text] [Related]
9. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
[TBL] [Abstract][Full Text] [Related]
12. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
Dardano A; Bianchi C; Del Prato S; Miccoli R
Vasc Health Risk Manag; 2014; 10():465-75. PubMed ID: 25143741
[TBL] [Abstract][Full Text] [Related]
13. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
[TBL] [Abstract][Full Text] [Related]
14. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
[TBL] [Abstract][Full Text] [Related]
15. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
Demir T; Turan S; Unluhizarci K; Topaloglu O; Tukek T; Gogas Yavuz D
Front Endocrinol (Lausanne); 2021; 12():616514. PubMed ID: 33776914
[TBL] [Abstract][Full Text] [Related]
16. Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.
Hirose T; Awata T; Yamamoto Y; Hemmingsen MP
Expert Opin Biol Ther; 2018 Jan; 18(1):77-85. PubMed ID: 29017373
[TBL] [Abstract][Full Text] [Related]
17. Review of Clinical Profile of IDegAsp.
Unnikrishnan AG; Singh AK; Modi KD; Saboo B; Garcha SC; Rao PV
J Assoc Physicians India; 2015 May; 63(5 Suppl):15-20. PubMed ID: 26548030
[TBL] [Abstract][Full Text] [Related]
18. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
Heise T; Tack CJ; Cuddihy R; Davidson J; Gouet D; Liebl A; Romero E; Mersebach H; Dykiel P; Jorde R
Diabetes Care; 2011 Mar; 34(3):669-74. PubMed ID: 21285389
[TBL] [Abstract][Full Text] [Related]
19. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]